Subscribe To
Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...
November 3, 2023, 8:30 pm
Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance
In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...
November 3, 2023, 8:30 pm
Coherus presents data from next-generation immuno-oncology programs at 38th annual meeting of society for immunotherapy of cancer (sitc)
– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development ...
November 3, 2023, 12:30 pm
Turnstone biologics presents preclinical data highlighting potential for selected tumor-infiltrating lymphocyte (til) therapy in solid tumors at the 2023 society for immunotherapy of cancer (sitc) ann
Presentations showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive ...
November 3, 2023, 10:00 am
In8bio to present new positive data from phase 1 trial of inb-100 at 2023 american society of hematology (ash) annual meeting
New data on the completed dose-escalation of this Phase 1 trial highlights promising efficacy of INB-100 in patients with hematologic malignancies; up...
November 2, 2023, 1:17 pm
In8bio to present new positive data from phase 1 trial of inb-100 at 2023 american society of hematology (ash) annual meeting
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta ...
November 2, 2023, 9:17 am
Corvus pharmaceuticals to present new interim soquelitinib data from its phase 1/1b t cell lymphoma trial at the 65th american society of hematology (ash) annual meeting & exposition
BURLINGAME, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today ...
November 2, 2023, 9:15 am
Molecular partners to present initial data from ongoing phase 1/2a trial of mp0533 for patients with relapsed/refractory aml and aml/mds at the 65th ash annual meeting and exposition
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (...
November 2, 2023, 2:00 am
Corvus pharmaceuticals announces publication of preclinical data demonstrating potential of itk inhibition with soquelitinib as a novel approach to t cell-mediated inflammatory and immune diseases
Data demonstrated soquelitinib was active in six inflammatory/immune disease models and provides rationale for development in a range of additional Th...
November 1, 2023, 11:31 pm
Cell lysis and disruption market to hit usd 15.5 billion by 2032, growing at a cagr of 12.9% | says transparency market research inc.
Automation in cell lysis and disruption processes is on the rise, allowing for higher throughput and reproducibility. The trend is particularly signif...
October 31, 2023, 4:30 pm
Cell therapy market revenue to cross usd 54.6 million by 2032; registering at a cagr of 18.7% – says, transparency market research
Increasing research and innovations in treatment methods will continue to grow the market. Increasing investments and an aging population will lead to...
October 26, 2023, 9:33 am
Sensei biotherapeutics to present initial clinical data from dose escalation trial of sns-101 at 2023 sitc annual meeting
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discove...
October 25, 2023, 9:05 am
Verizon's earnings beat driven by home and business internet, wireless subscribers fall
Verizon (VZ)'s home and business wireless business boosted third-quarter earnings even as the telecom giant los...
October 24, 2023, 10:05 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line set...
October 22, 2023, 10:01 am
